Company overview
PhoreMost is a UK-based biopharmaceutical company specializing in targeted protein degradation (TPD) through its proprietary SITESEEKER and GlueSEEKER platforms. These technologies enable phenotypic screening to identify novel druggable targets across the proteome and develop molecular glue degraders for oncology and inflammation. The company collaborates with partners like Arvinas to advance degrader therapeutics.
PhoreMost is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include targeted protein degradation, siteseeker, glueseeker, molecular glue degraders, tpd platforms.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.phoremost.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- targeted protein degradation, siteseeker, glueseeker, molecular glue degraders, tpd platforms
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are PhoreMost's key platforms for targeted protein degradation?
- PhoreMost's SITESEEKER platform performs phenotypic screening to identify novel druggable targets in live cells, while GlueSEEKER enables high-throughput discovery of molecular glue degraders by engineering E3 ligases.
- What therapeutic areas does PhoreMost target?
- PhoreMost focuses on oncology and inflammation, progressing a pipeline of degrader therapeutics for undruggable targets.
- Does PhoreMost offer partnerships or collaborations?
- Yes, PhoreMost collaborates with companies like Arvinas on multiple therapeutic targets, providing research funding, milestones, and access to its screening platforms.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
